BR0313425A - Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial - Google Patents

Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial

Info

Publication number
BR0313425A
BR0313425A BR0313425-3A BR0313425A BR0313425A BR 0313425 A BR0313425 A BR 0313425A BR 0313425 A BR0313425 A BR 0313425A BR 0313425 A BR0313425 A BR 0313425A
Authority
BR
Brazil
Prior art keywords
macrolide compound
ocular allergy
ophthalmic composition
commercial package
allergy treatment
Prior art date
Application number
BR0313425-3A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of BR0313425A publication Critical patent/BR0313425A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSIçãO OFTáLMICA PARA TRATAMENTO DE ALERGIA OCULAR, USO DO COMPOSTO DE MACROLìDEO E PACOTE COMERCIAL". A invenção provê composições oftálmicas e métodos para tratar dos sintomas de alergias oculares. O ingrediente de princípio ativo nessas composições e métodos é o composto de macrolídeo, tal como tacrolimus, ascomicina e rapamicina e seus derivados. São também providos concentrações ótimas e esquemas de dosagem.
BR0313425-3A 2002-08-09 2003-08-08 Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial BR0313425A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40206102P 2002-08-09 2002-08-09
PCT/JP2003/010105 WO2004014373A1 (en) 2002-08-09 2003-08-08 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases

Publications (1)

Publication Number Publication Date
BR0313425A true BR0313425A (pt) 2005-07-05

Family

ID=31715781

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313425-3A BR0313425A (pt) 2002-08-09 2003-08-08 Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial

Country Status (10)

Country Link
US (1) US20050239813A1 (pt)
EP (1) EP1536793A1 (pt)
JP (2) JP2005536531A (pt)
KR (1) KR20050054913A (pt)
CN (1) CN1674896A (pt)
AU (1) AU2003256068A1 (pt)
BR (1) BR0313425A (pt)
CA (1) CA2495103A1 (pt)
MX (1) MXPA05001575A (pt)
WO (1) WO2004014373A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1259049C (zh) * 2001-07-06 2006-06-14 苏坎波公司 包含白介素－2抑制剂和抗菌剂的局部给药组合物
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
PL1848431T3 (pl) 2005-02-09 2016-08-31 Santen Pharmaceutical Co Ltd Ciekłe formulacje do leczenia chorób lub stanów
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
CN1965825B (zh) * 2005-11-17 2011-07-06 洪晶 一种治疗眼部免疫性疾病及抑制增殖、新生血管的眼表用药
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN103127100A (zh) 2006-03-23 2013-06-05 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂和方法
KR100891313B1 (ko) 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR101632042B1 (ko) * 2014-06-30 2016-06-21 주식회사 인트론바이오테크놀로지 Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0406791T3 (da) * 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
WO1992019278A1 (en) * 1991-04-26 1992-11-12 Kurume University Use of macrolide compounds for eye diseases
WO2000066122A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
CN1259049C (zh) * 2001-07-06 2006-06-14 苏坎波公司 包含白介素－2抑制剂和抗菌剂的局部给药组合物
WO2003043650A1 (en) * 2001-11-21 2003-05-30 Sucampo Ag Use of fk506 and analogues for treating allergic diseases

Also Published As

Publication number Publication date
CN1674896A (zh) 2005-09-28
WO2004014373A1 (en) 2004-02-19
KR20050054913A (ko) 2005-06-10
US20050239813A1 (en) 2005-10-27
EP1536793A1 (en) 2005-06-08
JP2005536531A (ja) 2005-12-02
AU2003256068A1 (en) 2004-02-25
MXPA05001575A (es) 2005-08-19
JP2011012071A (ja) 2011-01-20
CA2495103A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
BR0313425A (pt) Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial
CU23423B7 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea
CO5631443A2 (es) Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales
CL2004000788A1 (es) Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
TW200700392A (en) Novel compounds
AR032136A1 (es) Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
BR0209518A (pt) Novos derivados arilheteroalquilamina
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
BRPI0409882A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
ATE233754T1 (de) Diphenyl-piperidin derivate
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
NZ509105A (en) Cyclic 24-membered depsipeptides for controlling ectoparasites
BRPI0409878A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]